BioXcel Therapeutics, Inc. Forecast, price target & analysts
BioXcel Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
BioXcel Therapeutics, Inc. Classifications & Recommendation:
BioXcel Therapeutics, Inc. Price Target
| Target Price | $11.22 |
| Price | $2.02 |
| Potential |
455.45%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target BioXcel Therapeutics, Inc. 2026 .
The average BioXcel Therapeutics, Inc. target price is $11.22.
This is
455.45%
register free of charge
$69.30
3,330.69%
register free of charge
$1.01
50.00%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend BioXcel Therapeutics, Inc. to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BioXcel Therapeutics, Inc. stock has an average upside potential 2026 of
455.45%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.27 | 0.73 |
| 64.49% | 67.75% | |
| EBITDA Margin | -2,841.41% | -7,089.37% |
| 76.56% | 149.50% | |
| Net Margin | -2,625.55% | -5,068.32% |
| 79.76% | 93.04% |
7 Analysts have issued a sales forecast BioXcel Therapeutics, Inc. 2025 . The average BioXcel Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an BioXcel Therapeutics, Inc. EBITDA forecast 2025. The average BioXcel Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 BioXcel Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average BioXcel Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -23.51 | -5.60 |
| 76.10% | 76.18% | |
| P/E | negative | |
| EV/Sales | 178.89 |
7 Analysts have issued a BioXcel Therapeutics, Inc. forecast for earnings per share. The average BioXcel Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioXcel Therapeutics, Inc....
Current BioXcel Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Sep 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
| LUCID CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Jul 15 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 23 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Sep 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 15 2025 |
|
Locked
LUCID CAPITAL MARKETS:
Locked
➜
Locked
|
Jul 15 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 23 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
